By Thomas Scharnitz, MD Held as a virtual event this year due to the COVID-19 pandemic, the 29th Congress of the EADV hosted nearly 11,000 attendees logging in from all over the world. Psoriasis played an important role in the EADV agenda, according to conference planners, in recognition that the disease affects 2-3% of the world's population. The EADV virtual congress featured sessions on psoriasis genetics and pathophysiology as well as presentations on promising therapies, from "classical treatments to small molecules," psoriasis and pregnancy, biologics and the treatment of cardiovascular inflammation, and more. The following are summaries of the EADV sessions with a focus on psoriasis.
Latest news INSIDE LOOK campaign raises awareness about plaque psoriasisJune 16, 2021Amgen and Otezla® (apremilast) have partnered with Allan Avendaño, makeup artist to Hollywood A-listers, for the INSIDE LOOK campaign to share his journey living with plaque psoriasis and the difficulties of being in his demanding role and dealing with a chronic skin condition. Dermavant submits New Drug Application to FDA for tapinarof cream for the treatment plaque psoriasisJune 09, 2021Dermavant Sciences announced on June 3, 2021 that it has submitted a New Drug Application to the U.S. Food and Drug Administration for tapinarof for the treatment of mild, moderate and severe plaque psoriasis in adult patients. IPC International Fellow wins first prize for 2021 RADLA Poster PresentationJune 09, 20212019 IPC Fellow Romina Contreras was recognized at the 2021 Virtual RADLA Congress, winning first prize for her poster presentation. New data from the PsoProtect RegistryJune 01, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1,118 cases. More News
Stay informed Join the email list to receive the latest information on psoriasis meetings, manuscripts and research. SUBSCRIBE